Wound healing is a highly specialized dynamic process for the repair of damaged/injured tissues through an intricate mechanism. Any failure in the normal wound healing process results in abnormal scar formation, and a chronic state which is more susceptible to infections. Researchers from Monash University in Australia and Osaka University in Japan have demonstrated that the removal of a specific subtype of sensory neurons containing the Nav1.8+ ion channel significantly impairs skin wound repair and muscle regeneration following injury.

Teijin Pharma Ltd. has entered into an exclusive global licensing agreement with Bioprojet under which Teijin Pharma grants Bioprojet Pharma SAS exclusive worldwide rights to research, develop, manufacture and commercialize an investigational candidate for narcolepsy.

Mina Therapeutics Ltd. has announced a research collaboration and licensing agreement option with Nippon Shinyaku Co. Ltd. for the discovery and potential development and commercialization of small activating RNA (RNAa) therapeutic candidates targeting rare neurodegenerative diseases for which there are currently no treatment options.

Inmed Pharmaceuticals Inc. has reported new preclinical data demonstrating INM-901’s pharmacological effects for the potential treatment of Alzheimer’s disease. Several preclinical studies were conducted in well-characterized Alzheimer’s disease models.